ATA-200, Atamyo Therapeutics’ Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5, Reaches Key Milestones with the Filing of a Clinical Trial Application in Europe and a Non-Dilutive Financing from France 2030 Program
Retrieved on:
Tuesday, September 19, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Muscular dystrophy, Clinical trial, Pathology, Hope, CTA, Biomarker, AAV, Weakness, Patient, SGCG, Liver, Entrepreneurship, Therapy, Environment, Disease, DSM-IV codes, Safety, LGMD, Pharmaceutical industry, Vaccine, Dietary supplement, FKRP
No curative treatment exists for this disease,” said Dr Sophie Olivier, Chief Medical Officer of Atamyo.
Key Points:
- No curative treatment exists for this disease,” said Dr Sophie Olivier, Chief Medical Officer of Atamyo.
- “ATA-200 incorporates a new promoter that enhances the liver and cardiac safety of gene therapy,” said Isabelle Richard, Ph.D., Co-founder and Chief Scientific Officer of Atamyo.
- ATA-200, the gene therapy for LGMD2C/R5, delivers a normal copy of the gene for production of γ-sarcoglycan.
- In addition to its LGMD2C/R5 gene therapy, Atamyo is developing a clinical trial with ATA-100 gene therapy for LGMD2I/R9, related to deficiencies in FKRP; and is in IND-enabling studies for LGMD2A/R1, related to deficiencies in calpain protein.